Rottenstein Law Group Responds to DePuy President’s Testimony That ASR Hip Implant Isn’t Defective

The Rottenstein Law Group, which represents clients in DePuy ASR lawsuits, is following the trial closely and notes that in a previous ASR hip recall trial in Los Angeles the jury awarded the plaintiff $8.34 million after finding the ASR’s design defective.

Chicago (PRWEB) March 18, 2013

The president of DePuy Orthopaedics asserted last week under questioning in the second DePuy ASR hip trial that the metal-on-metal hip implant was recalled because of a high rate of corrective surgery required in patients—and not because the device’s design was defective.* The Rottenstein Law Group, which represents clients in DePuy ASR lawsuits, is following the trial closely and notes that in a previous ASR hip recall trial in Los Angeles the jury awarded the plaintiff $8.34 million after finding the ASR’s design defective. The firm maintains an informational website on the recall and lawsuits as a result of the recall on http://www.depuyrecallnewscenter.com.

According to Bloomberg, Andrew Ekdahl, whose DePuy is a subsidiary of Johnson & Johnson, told the jury that the revision rate (corrective surgery rate) was “unacceptable” and that was the reason for the August 2010 recall. Carol Strum, 54, filed the lawsuit against Johnson & Johnson and DePuy (In Re DePuy ASR Hip Litigation, No. 10-L-10506, Cook County Circuit Court), alleging that the company failed to warn of the risks associated with the device’s defective design.

Read full story at PRWeb.com: Rottenstein Law Group Responds to DePuy President’s Testimony That ASR Hip Implant Isn’t Defective